Start Date
February 28, 1998
Primary Completion Date
May 31, 2001
Study Completion Date
May 31, 2001
leflunomide
procarbazine hydrochloride
Memorial Sloan-Kettering Cancer Center, New York
Herbert Irving Comprehensive Cancer Center, New York
Albert Einstein Comprehensive Cancer Center, The Bronx
Cancer Center of Albany Medical Center, Albany
Western Pennsylvania Cancer Institute, Pittsburgh
Mount Sinai Comprehensive Cancer Center, Miami Beach
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Arthur G. James Cancer Hospital - Ohio State University, Columbus
Barrett Cancer Center, The University Hospital, Cincinnati
Henry Ford Hospital, Detroit
University of Iowa College of Medicine, Iowa City
Medical College of Wisconsin, Milwaukee
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
University of Texas - MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Denver
Arizona Cancer Center, Tucson
Beckman Research Institute, City of Hope, Los Angeles
St. Francis Hospital, San Francisco
St. Joseph's Hospital and Medical Center, Phoenix
USC/Norris Comprehensive Cancer Center, Los Angeles
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles
Medical College of Georgia Hospital and Clinics, Augusta
Indiana University Cancer Center, Indianapolis
Beth Israel Deaconess Medical Center, Boston
University of Massachusetts Memorial Medical Center, Worcester
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Nebraska Medical Center, Omaha
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill
Rhode Island Hospital, Providence
Vanderbilt Cancer Center, Nashville
Simmons Cancer Center - Dallas, Dallas
University of Washington Medical Center, Seattle
Cross Cancer Institute, Edmonton
Cancer Care Ontario-London Regional Cancer Centre, London
Princess Margaret Hospital, Toronto
Lead Sponsor
Pfizer
INDUSTRY